Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

CEQUA®, Novel Therapy Discovered for Dry Eye Disease

Sun Pharmaceutical Industries dicovered CEQUA®, a novel therapy for the treatment of dry eye disease.

CEQUA® (cyclosporine ophthalmic solution 0.09% w/v), calcineurin inhibitor  immunomodulator which rises tear flow in patients with keratoconjunctivitis sicca (dry eye). It is a new clear preservative-free nanomicelle water solution that helps to improve the penetration of the active ingredient ciclosporin in ocular tissues.

CEQUA® is the first dry ophthalmic treatment delivered with nanoscale NCELL®* technology. This unique NCELL ®* Technology and formulation provides a better dose than cyclosporine emulsion 0.05 percent. It is suitable for patients with inflammatory dry eye disease (DED), the most common disease.

NCELL®* Technology makes use of new encapsulation that surrounds CEQUA® active ingredient ciclosporin allowing cyclosporine to pass through layer of the tear film and releases it into the  tissues of the eye where it is most needed.

The existing treatment options for dry eye disease consists of certain limitations resuting in a strong unmet need. The introduction of CEQUA® will become a new treatment option for individuals with this disease.

In the daily practise, cases of dry eye diseases have raised, due to increased screen time and other lifestyle changes, hence resulting for more treatment options. 

Global clinical studies have shown that CEQUA® offers quick results and is comfortablly suitable for patients from the start of the treatment. 

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024